Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.

Experimental gerontology - 1 Jul 2002

Weksler Marc E, Relkin Norman, Turkenich Rimma, LaRusse Susan, Zhou Ling, Szabo Paul

Abstract excerpt

Active immunization with the human amyloid peptide (Abeta42) or passive immunization with anti-Abeta42 antibodies protects mice that express a mutant human amyloid precursor protein (APP) transgene from cerebral amyloid deposits. If anti-Abeta42 antibodies protect APP-transgenic mice, a model of Alzheimer's disease (AD), a high titer of anti-Abeta42 antibodies may protect humans from AD. The titer of anti-Abeta42...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Protein Precursor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoprotein E4

Share to Apolipoproteins E

Share to Enzyme-Linked Immunosorbent Assay

Share to Hemagglutinin Glycoproteins, Influenza Virus

Share to Immunization

Share to Immunoglobulin G

Source

Identifiers

PMID: 12086704
DOI: 10.1016/s0531-5565(02)00029-3

Genes

APP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.PMID 12086704Read ↗

Beta-amyloid auto-antibodies are reduced in Alzheimer's disease.Semantic proximity Read ↗

Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer DiseaseSemantic proximity Read ↗

T Cell Responses to Neural Autoantigens Are Similar in Alzheimer’s Disease Patients and Age-Matched Healthy ControlsSemantic proximity Read ↗

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline.Semantic proximity Read ↗

Antibody against Small Aggregated Peptide Specifically Recognizes Toxic Aβ-42 Oligomers in Alzheimer’s DiseaseSemantic proximity Read ↗

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice.Semantic proximity Read ↗

Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls.Semantic proximity Read ↗

Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report.Semantic proximity Read ↗

Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease.Semantic proximity Read ↗

Anti-A 42- and anti-A 40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse modelSemantic proximity Read ↗

Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.Semantic proximity Read ↗

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.